Status: Recruiting
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
Participants needed: 65
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Ashvattha Therapeutics, Inc.Updated: May 2, 2025Locations: 3
Eligibility criteria
Has the ability to understand and sign the written ICF and local medical privacy... [+34]
Body weight >120 kg [+23]